{"id":"W4322772114","doi":"10.1158/1538-7445.sabcs22-ot1-03-04","title":"Abstract OT1-03-04: Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators’ choice of chemotherapy in previously-treated, inoperable or metastatic HR+/HER2– breast cancer: TROPION-Breast01","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Vinorelbine; Eribulin; Internal medicine; Chemotherapy; Oncology; Breast cancer; Gemcitabine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107956,0.000670112,0.001258501,0.0003023761,0.0002194508,0.0008793863,0.0005362639,0.000820545,0.01392511],"category_scores_gemma":[0.001369882,0.0002416467,0.001341974,0.0003399427,0.0005389025,0.0006488279,0.0003090662,0.002882109,0.00109711],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001157641,"about_ca_system_score_gemma":0.001242742,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001375538,"about_ca_topic_score_gemma":0.003708533,"domain_scores_codex":[0.9995134,0.0002489685,0.00002829843,0.00007777405,0.00004072603,0.00009085079],"domain_scores_gemma":[0.999086,0.0002464857,0.0002135959,0.00005322089,0.00004688269,0.0003538184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8989061,0.007028304,0.00149311,0.0007806182,0.001069493,0.00005061822,0.0000589599,0.000861194,0.004493379,0.0004101271,0.006719476,0.07812863],"study_design_scores_gemma":[0.7289855,0.2470365,0.007675822,0.0002669489,0.001906514,0.0001818794,0.00008275112,0.001846593,0.002993405,0.0006541538,0.008338469,0.00003156493],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9724855,0.008299914,0.0006017514,0.001922515,0.0007831399,0.001647381,0.003762924,0.0001539638,0.01034298],"genre_scores_gemma":[0.9875162,0.002424439,0.000709087,0.001239755,0.0003174295,0.0008928996,0.002503688,0.00003571529,0.004360933],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01392511,"threshold_uncertainty_score":0.04658413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07280313990434058,"score_gpt":0.4282112842062609,"score_spread":0.3554081443019203,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}